A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression
Conditions
Interventions
- DRUG: IBI363(PD-1/IL-2a-bias)
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology